Lexaria Bioscience
LEXX
10 hedge funds and large institutions have $2.93M invested in Lexaria Bioscience in 2021 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 3 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
64% more capital invested
Capital invested by funds: $1.78M → $2.93M (+$1.14M)
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
11% more funds holding
Funds holding: 9 → 10 (+1)
1.95% more ownership
Funds ownership: 6.24% → 8.18% (+1.9%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$300K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$155K |
| 3 |
ICM
Invenomic Capital Management
Boston,
Massachusetts
|
+$125K |
| 4 |
Renaissance Technologies
New York
|
+$102K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$1.49K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$84K |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$2.68K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
ICM
1
Invenomic Capital Management
Boston,
Massachusetts
| $2.22M | +$125K | +21,009 | +7% |
|
|
2
Geode Capital Management
Boston,
Massachusetts
| $352K | +$300K | +50,385 | New |
|
|
3
Vanguard Group
Malvern,
Pennsylvania
| $182K | +$155K | +25,976 | New |
|
|
4
Renaissance Technologies
New York
| $120K | +$102K | +17,200 | New |
|
|
EWM
5
Edge Wealth Management
New York
| $24K | – | – | – |
|
|
MFM
6
MD Financial Management
Ottawa,
Ontario, Canada
| $23K | – | – | – |
|
|
7
Royal Bank of Canada
Toronto,
Ontario, Canada
| $2K | -$2.68K | -451 | -64% |
|
|
TRCT
8
Tower Research Capital (TRC)
New York
| $2K | +$1.49K | +251 | New |
|
9
Osaic Holdings
Scottsdale,
Arizona
| $1K | +$18 | +3 | +2% |
|
|
10
Citadel Advisors
Miami,
Florida
| – | -$84K | -14,915 | Closed |
|
|
11
Bank of America
Charlotte,
North Carolina
| – | -$1K | -145 | Closed |
|
LEXX Hedge Fund Activity: Q2 2021 in Review
10 of the 5,746 institutional investors tracked by Wall St. Rank reported a position in Lexaria Bioscience (LEXX) for Q2 2021, worth a combined $2.93M — up 64% from $1.78M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new LEXX positions and 3 closed out — a net gain of 1 holder — while 2 added to existing stakes and 1 trimmed.
The largest buyer was Geode Capital Management, opening a new position worth an estimated $300K. The largest seller was Citadel Advisors, exiting entirely with an estimated $84K sold.
- 10 institutional investors held Lexaria Bioscience (LEXX) as of Q2 2021, up from 9 in Q1 2021.
- Funds reported $2.93M of Lexaria Bioscience stock for Q2 2021, up 64% quarter-over-quarter.
- 4 funds opened new Lexaria Bioscience positions in Q2 2021 and 3 closed out, a net change of +1 holder.
- The largest Lexaria Bioscience buyer in Q2 2021 was Geode Capital Management, an estimated $300K added.
- The largest Lexaria Bioscience seller in Q2 2021 was Citadel Advisors, an estimated $84K sold.
Based on aggregated 13F filings for Q2 2021.